Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: Data from a 13-week double-blind, placebo-controlled, parallel, multicenter study

Journal of Human Hypertension

Volumn 18, Issue 9, 2004, Pages 655-661

  Punzi, H A ^a   Punzi, C F ^a   Chattam, Martin S ^b   Hsi, Steven D ^c   Norton, John D ^d   O'Barr Jr , Thomas ^e   Sant Ram, Deepak ^f   Oandasan, Oscar C ^g   Murphy, Dale P ^h   White, William B ⁱ   Lewin, Andrew J ^j   Carr, Albert A ^k   Bordenave, Kristine ^al   Gilderman, Larry I ^l   Hammond, Paul G ^m   Weinberg, Marc S ⁿ   Bowman, Steven C ^o   Vargas, Ramon ^p   Punzi, Henry A ^q   DeAbate, C Andrew ^r   O'Connor, Daniel T ^s   Schmidt, J Rodney ^t   Littlejohn, Thomas W ^u   Calhoun, David A ^v   Sutton, Joseph M ^w   Habib, Gabriel B ^x   Esper, William A ^y   Neutel, Joel M ^z   Caplan, Joseph A ^aa   Elliot, William J ^ab   Powell, R Walter ^ac   Grossman, Colby H ^ad   Cangiano, Jose L ^ae   Gamel, William G ^af   Weiss, Robert J ^ag   Iteld, Bruce J ^ah   Acosta, Jamie H ^ai   Lopez, Margarita F ^aj   Munoz, Ernesto G ^ak   Erwteman, Theodor M ^al   Spilthooren, Francois ^al   Boye, Alain ^al   Dubourg, Dominique ^al   Marty, Jacque ^al   Angotti, Jacque ^al   more..

^a Punzi Medical Center   (United States)

^b Arizona Clinical Trials Inc   (United States)

^c Albuquerque Clinical Trials Inc   (United States)

^d Penrose St Francis   (United States)

^e Adult Primary Care   (United States)

^f Sant Ram Medical Associates   (United States)

^g R/D Clinical Research Inc   (United States)

^h SUMMA HEALTH SYSTEM   (United States)

ⁱ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^j NATIONAL RESEARCH INSTITUTE   (United States)

^k Circulatory Disease Center   (United States)

^l University Clinical Research Inc   (United States)

^m VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁿ Hypertension and Nephrology Inc   (United States)

^o Tampa Bay Medical Research Inc   (United States)

^p General Clinical Research Center New Orleans   (United States)

^q Trinity Hypertension Research Center   (United States)

^r Woodmere Medical Center   (United States)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t Puget Sound Partnership   (United States)

^u Piedmont Medical Research Associates   (United States)

^v UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^w Northern Ohio Medical Services Inc   (United States)

^x MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^y Erie Heart and Lung Center   (United States)

^z Orange County Research Center   (United States)

^aa Del E Webb Memorial Hospital   (United States)

^ab RUSH UNIVERSITY MEDICAL CENTER   (United States)

^ac Health Care Inc   (United States)

^ad Palmetto Clinical Research   (United States)

^ae San Juan Veterans Hospital   (United States)

^af Austin Inc   (United States)

^ag St Mary's Regional Med Center   (United States)

^ah Lakeland Medical Center   (United States)

^ai INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^aj INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^ak Regional Hospital   (Mexico)

^al NONE

more..

Author keywords

Angiotensin II antagonist; Angiotensin receptor blocker; Elderly hypertension; Eprosartan; Isolated systolic hypertension; Pulse pressure

Indexed keywords

EPROSARTAN; HYDROCHLOROTHIAZIDE; PLACEBO;

ADULT; AGE; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ASTHENIA; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; FOLLOW UP; GENDER; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PARALLEL DESIGN; PULSE PRESSURE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; SINGLE BLIND PROCEDURE; SITTING; STANDING; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

ACRYLATES; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; SODIUM CHLORIDE SYMPORTER INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 4544349394     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001704     Document Type: Article

References (19)

1. Himmelman A et al. Isolated systolic hypertension: an important cardiovascular risk factor. Blood Press 1998; 7: 197-207.
2. Izzo JL, Levy D, Black HR. Clinical advisory statement: importance of systolic blood pressure in older Americans. http:www.nhlbi.nih.gov/health/prof/heart/hbp/hbpstmt/index.htm.
3. Franklin SS et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
4. He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens 1997; 17 (Suppl 2): S2-S13.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
6. Mulrow CD et al. Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA 1994; 272: 1932-1938.
7. Systolic Hypertension in the Elderly Program Cooperative Research Group. Implications of the systolic hypertension in the elderly program. Hypertension 1993; 21: 335-343.
8. Staessen JA et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
9. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55: 713-718.
10. Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999; 11(1): 9-14.
11. Ruilope L, Jager B, Prichard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press 2001; 10: 223-229.
12. Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. J Hypertens 1999; 17: 129-136.
13. Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999; 8: 114-121.
14. Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 2002; 16: 109-176.
15. Ruilope L, Jager B. Eprosartan for the treatment of hypertension. Expert Opin Pharmacother 2003; 491: 107-114.
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
17. Messerli FH. ALLHAT, or the soft science of the secondary end point. Ann Intern Med 2003; 139 (9): 777-780.
18. Breeze E, Rake EC, Donoghue MD, Fletcher AE. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension. J Hum Hypertens 2001; 15: 857-862.
19. Blum RA, Kazierad DJ, Tenero DM. A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. Pharmacotherapy 1999; 19 (4 Pt 2): 79S-85S.